15:55 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
11:00 , Nov 15, 2018 |  BC Extra  |  Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
19:20 , Jul 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Schizophrenia; depression Cell culture studies suggest inhibiting DISC1 - FBXW7 binding could help treat schizophrenia and major depressive disorder (MDD). In human neuroprogenitor cells (NPCs) differentiated from induced pluripotent stem (iPS) cells generated from...
20:39 , Jul 20, 2017 |  BC Extra  |  Preclinical News

FBXW7-DISC1 complex linked to schizophrenia

In a paper, researchers showed that F-box and WD repeat domain containing 7 (FBXW7; FBW7) controls levels of a scaffold protein, disrupted in schizophrenia 1 (DISC1) , which is deficient in hereditary schizophrenia. The research...
07:00 , Sep 15, 2016 |  BC Innovations  |  Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
07:00 , Aug 29, 2013 |  BC Innovations  |  Tools & Techniques

DISCerning schizophrenia in mice

Despite genetic advances in schizophrenia research, a lack of predictive preclinical models has hampered the development of new therapeutics. Now, a team at The Johns Hopkins University has created a transgenic mouse model of prefrontal...
07:00 , Aug 15, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Dominant negative-disrupted in schizophrenia 1 (DISC1) mouse models of prefrontal cortex dysfunction Mice expressing a dominant negative form of DISC1 (DN-DISC1) could help model cognitive...
08:00 , Feb 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression; anxiety Glucocorticoid receptor (GCCR); disrupted in schizophrenia 1 (DISC1) Mouse studies suggest blocking the glucocorticoid receptor in the brain could help treat adult-onset neuropsychiatric...
08:00 , Feb 14, 2013 |  BC Innovations  |  Targets & Mechanisms

Stressing out over depression and anxiety

Two teams have shown that enhanced glucocorticoid signaling in the brain triggers aberrant behavior in mouse models of depression and anxiety. 1,2 The groups are now using the mice to study the mechanisms underlying the...
07:00 , Apr 19, 2010 |  BioCentury  |  Emerging Company Profile

Afraxis: Backing PAK1

Most treatments for Fragile X syndrome only alleviate the symptoms, such as anxiolytics for anxiety, but Afraxis Inc. is attempting to modify the disease by attacking the underlying biology of synaptic dysfunction. The company is...